The 2026 Evidence Says Yes-But Timing and Severity Matter
“The short answer is yes, but the risk is not uniform. The risk is disproportionately found among the elderly and those with preexisting conditions, but it is real, and the most recent studies, published in 2026, show how deep and how long that shadow extends. The latest data from 2026 show that COVID-19 leaves a measurable cardiovascular footprint; heart attacks and strokes are higher in the immediate aftermath of infection, and for those who have been hospitalized the risk of major cardiovascular events persists for at least a year after the onset of the infection.
The Risk Peaks Early, Then Declines
It is in a large population study of 162,471 adults from the Rochester Epidemiology Project, completed in 2026, that the sharpest clustering of major adverse cardiovascular events (heart attacks, strokes, death) was observed during the first thirty days after infection, which later fell off.
A pronounced gradient of age was revealed. The 30-day event rate in adults aged 80 and older in the pre-Delta era was 140 per 1,000 person-months, whereas during Omicron the rate fell to 36 per 1,000 person-months, still high but far below the initial epidemic levels. The lowest age group was those under 40, whose rate was low across all eras, below 1 per 1,000 person-months.
An independent self-controlled case series by Kaiser Permanente Southern California, presented in 2026, quantified this acute danger even more directly. In the 15 days after SARS-CoV-2 infection, the relative incidence of acute myocardial infarction was about nineteen to twenty-two times higher than in unexposed periods, and the risk of ischemic stroke was about ten to twelve times higher. But most importantly, vaccination did not increase the risk: relative incidence after vaccination was below 1.0.
Hospitalized Patients Face a Longer Shadow
Hence the risk for the person who was sick enough to be hospitalized with COVID-19 did not disappear when the patient left. In 2026, the Medicare analysis of 1.18 million beneficiaries aged 65 and older who had been hospitalized for the same condition in the Omicron era showed that within a year of their discharge from the hospital, 48.8 percent of them had suffered a combination of heart attack, stroke, heart failure, or other major illness.
This figure was slightly lower than the pre-Omicron era (49.3%) but much higher than that of the historical influenza cohort (only 33.4%). The Omicron group had a reduced risk of death compared to the pre-Omicron group, but an increased risk of heart attack, stroke or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or heart failure hospitalization. In plain words: the patients who survived the acute phase of the infection were subsequently subject to more heart damage.
Subclinical heart damage was seen even in survivors with mild initial symptoms. An analysis of nine high-quality studies covering more than 400,000 survivors, with follow-up of up to 25 months, revealed a 35% increased risk of new-onset heart failure (adjusted hazard ratio 1.35; 95% confidence interval 1.14–1.60). This risk was especially high in immunocompromised kidney transplant recipients (hazard ratio 2.32), but also in younger adults under the age of 65 (hazard ratio 1.53), a finding that challenges the assumption that cardiovascular sequelae are primarily a problem of the elderly.
The Hypertensive Population Is Especially Vulnerable
A retrospective cohort of 75,180 hypertensive patients in the Montefiore Health System in 2026 provided crucial information. Those hospitalized for COVID-19 had a 40 percent higher risk of first-time heart attack, a 35 percent higher risk of stroke, and a 65 percent higher risk of major adverse cardiovascular events over up to 4.5 years of follow-up. Even those who did not need hospitalization showed a significant increase in heart failure (17 percent higher) and MACE (14 percent higher).
A dose-response effect was also found between the severity of COVID-19 and blood pressure. The risk of MACE rose by 75% in people with normal blood pressure, but by 126% in those with elevated blood pressure and by 148% in those with stage 1 hypertension. Pre-existing vascular vulnerability amplifies the viral insult.
The Mechanisms: Inflammation, Clotting, and Viral Persistence
Why does COVID-19 leave such a lasting mark on the heart? A narrative review published in Microorganisms in June 2026 summarizes the virological and immunological evidence: SARS-CoV-2 can enter cardiomyocytes, pericytes, and endothelial cells through ACE2-dependent pathways, and in certain autopsy series viral RNA and antigen have been detected in cardiovascular tissues months after symptom onset. Endothelial dysfunction, neutrophil extracellular trap formation, complement activation, and persistent thromboinflammation have been proposed as plausible mechanisms for arrhythmogenic remodeling and thromboembolic events.
Pretorius and Kell have put forward the microclot hypothesis, which posits that long COVID is characterized by thrombotic endotheliitis, hyperactivated platelets, and fibrinaloid microclots that resist fibrinolysis. This pathological state could explain both persistent symptoms and elevated cardiovascular risk. Although this mechanism is still under active investigation, it would seem to explain why COVID-19 leaves a cardiovascular shadow long after its acute phase.
The Pediatric Picture: Subtle but Real
The children were not entirely untouched. In a prospective study of 100 children and adolescents with post-COVID syndrome at Hannover Medical School, right ventricular global radial and circumferential strain on cardiac MRI was significantly decreased compared with healthy controls, and right ventricular mass index was increased, though left ventricular function remained normal. A separate 2026 case-control study of children aged 4–17 found a persistent reduction in left ventricular global longitudinal strain (GLS) up to one year after infection, indicating subclinical myocardial dysfunction, and elevated serum ICAM-1 levels in those with moderate to severe infections, suggestive of endothelial activation. Long-COVID symptoms were reported in 23.6% of the infected children, with fatigue being the most common.
The clinical significance of these pediatric findings is not yet fully understood. The changes are very slight and not really clinical, and they have not yet been found to be followed by overt heart disease. But they demonstrate that in spite of their age, the virus does not leave the heart completely untouched, even in children.
Vaccination Cuts the Cardiovascular Risk
But if the virus is the threat, there is no lack of proof that vaccination may avert it. A meta-analysis of twenty-three observational studies found that pre-infection COVID-19 vaccination was associated with significantly lower risks of composite cardiovascular/cerebrovascular events (HR 0.60), stroke (HR 0.75), acute coronary syndrome (HR 0.70), arrhythmias (HR 0.82), and venous thromboembolism (HR 0.51) following infection.
A large-scale cohort study in 2026 using the TriNetX Research Network, involving 30.3 million individuals, provided the most direct comparison between infection and vaccination so far. SARS-CoV-2 infection was associated with 3- to 5-fold increases in cardiovascular events in the acute phase, including myocarditis (RR 4.44 for men, RR 5.59 for women) and all-cause mortality (RR 4.53 for men), with risks persisting beyond nine months. BNT162b2 vaccination, by contrast, was associated with 65–76% reductions in major adverse cardiovascular events in the first three months, and post-infection vaccination (hybrid immunity) provided an additional 36–38% MACE reduction. Completing the two-dose primary series maximally reduced mortality (by 77%) and myocarditis (by 62%) compared with single dosing. The authors concluded that infection carries substantially greater and more sustained cardiovascular risk than vaccination across all comparisons and both sexes.
The Bottom Line for 2026
Are there more heart attacks and strokes now? In those who have had COVID-19, especially those who were hospitalized or who had hypertension, yes, there was a measurable rise in the risk. The first 30 days are the most dangerous, but in hospitalized people the risk of heart failure, stroke, and heart attack lasts for at least a year and is greater than in patients who were ill with the flu. The risk of new-onset heart failure is elevated by 35 percent across survivors, with a particular signal of concern in people under the age of 65.
For the general population, the state of affairs is more stable. Known risk factors, such as obesity, hypertension, diabetes, and smoking, continue to be the major drivers of heart disease; but to this picture of risk has been added a new, time-limited trigger, which is especially dangerous to those who are most vulnerable. Clearly, if you have contracted COVID-19 and have cardiovascular risk factors, the months after your infection are not the time to neglect your blood pressure or ignore your symptoms. And vaccination, by reducing the severity of the disease, lessens the heart damage to follow. The virus has always been the bigger danger, to the heart as much as to the lungs.
BY FRANK SHUMAN
SOURCES
- https://pubmed.ncbi.nlm.nih.gov/41957521/ — Hypertension and cardiovascular risk after COVID (75,180 patients)
- https://pubmed.ncbi.nlm.nih.gov/41976966/ — New-onset heart failure after COVID recovery (400,000+ survivors)
- https://pubmed.ncbi.nlm.nih.gov/42472854/ — Vaccination vs. infection: 30.3-million-person cohort
- https://pubmed.ncbi.nlm.nih.gov/42529825/ — Medicare beneficiaries hospitalized with COVID (1.18 million)